<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app19.us.archive.org';v.server_ms=1189;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-9858?contentType=xml', '20160930215607')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20160930215607/https://www.guideline.gov/summaries/downloadcontent/ngc-9858?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20160930215607/https://www.guideline.gov/summaries/downloadcontent/ngc-9858?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-9858?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20160930215607" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap">Aug</td>
		  <td class="c" id="displayMonthEl" title="You are here: 21:56:07 Sep 30, 2016">SEP</td>
		  <td class="f" nowrap="nowrap">Oct</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_prv_off.png" alt="Previous capture" width="14" height="16" border="0" /></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 21:56:07 Sep 30, 2016">30</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap">2015</td>
		  <td class="c" id="displayYearEl" title="You are here: 21:56:07 Sep 30, 2016">2016</td>
		  <td class="f" nowrap="nowrap">2017</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20160930215607*/https://www.guideline.gov/summaries/downloadcontent/ngc-9858?contentType=xml" title="See a list of every capture for this URL">1 capture</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-9858?contentType=xml","2016-09-30",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Optimal chemotherapy for recurrent ovarian cancer.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Fung Kee Fung M, Kennedy E, Francis J, Mackay H, Gynecologic Cancer Disease Site Group. Optimal chemotherapy for recurrent ovarian cancer. Toronto (ON): Cancer Care Ontario (CCO); 2011 Nov 21. Various p.&amp;nbsp;(Evidence-based series; no. 4-3).&amp;nbsp; [89 references]</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Fung Kee Fung M, Johnston M, Eisenhauer E, Elit L, Hirte H, Rosen R and the Gynecological Cancer Disease Site Group. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum. Toronto (ON): Cancer Care Ontario (CCO); 2001 Sep 21. (Evidence Summary Report No. 4-3).</p>
<p>The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from reviewing and updating activities.</p>
<p>Please visit the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34203&quot; title=&quot;CCO Web site&quot;>Cancer Care Ontario Web site</a> for details on any new evidence that has emerged and implications to the guidelines.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>On the basis of the available data from Phase III randomized controlled trials (RCTs), combined with expert opinion, the Gynecologic Cancer Disease Site Group recommends that:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Systemic therapy for recurrent ovarian cancer is not curative. As such, it is recognized that, to determine the optimal therapy, each patient needs to be assessed individually in terms of recurrence, sensitivity to platinum, toxicity, ease of administration, and patient preference. </li>
    <li>All patients should be offered the opportunity to participate in clinical trials, if appropriate. </li>
    <li>For patients with prior sensitivity to platinum-containing chemotherapy:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>All suitable patients should be offered the opportunity to participate in RCTs, if appropriate. </li>
        <li>If the option to participate in an RCT is not available, combination platinum-based chemotherapy should be considered, providing that there are no contraindications. The decision regarding which combination to use should be based on the considerations listed in the first bullet point above, including toxicity experienced with primary therapy, patient preference, and other factors. Recommended combinations are:
        <ul style=&quot;list-style-type: disc;&quot;>
            <li>Carboplatin and paclitaxel (C-P) </li>
            <li>Carboplatin and gemcitabine </li>
            <li>Carboplatin and pegylated liposomal doxorubicin (C-PLD) </li>
        </ul>
        </li>
        <li>If combination platinum-based chemotherapy is contraindicated, then a single platinum agent should be considered. Carboplatin has demonstrated efficacy across trials and has a manageable toxicity profile. </li>
        <li>If a single platinum agent is not being considered (e.g., because of toxicity), then monotherapy with paclitaxel, topotecan, or pegylated liposomal doxorubicin is a reasonable treatment option. </li>
    </ul>
    </li>
    <li>For patients with platinum-refractory or platinum-resistant disease:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Lower levels of response to treatment are expected for this group; therefore, the goals of treatment should be to improve quality of life (QOL) by extending the symptom-free interval, reducing symptom intensity, increasing progression free interval, or if possible, prolonging life. </li>
        <li>All suitable patients should be offered the opportunity to participate in clinical trials, if appropriate. </li>
        <li>Monotherapy with a non-platinum agent should be considered since there does not appear to be an advantage in the use of non-platinum-containing combination chemotherapy in this group of patients. Single-agent paclitaxel, topotecan, pegylated liposomal doxorubicin, and gemcitabine have demonstrated activity in this patient population and are reasonable treatment options. </li>
        <li>There is no evidence to support or refute the use of more than one line of chemotherapy in patients with platinum-refractory or platinum-resistant recurrences. There are many treatment options that have shown modest response rates but their benefit over best supportive care has not been studied in clinical trials. </li>
    </ul>
    </li>
</ul>
<p><strong>Modifications from 2006 Recommendations</strong></p>
<p>The recommendations listed above are predominantly unchanged from the 2006 version of this guideline, with the exception of the addition of C-PLD as a treatment option for platinum-sensitive recurrent ovarian cancer, the addition of single-agent gemcitabine as a treatment option for platinum-resistant ovarian cancer, and the clarification of the recommendation for participation in clinical trials.</p></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Recurrent epithelial ovarian cancer</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Assessment of Therapeutic Effectiveness"/>
      <fieldvalue value="Treatment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Obstetrics and Gynecology"/>
      <fieldvalue value="Oncology"/>
      <fieldvalue value="Surgery"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To evaluate what is the optimal chemotherapy treatment for women with recurrent ovarian cancer who have previously received platinum-based chemotherapy</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Women with recurrent epithelial ovarian cancer who have previously received platinum-based chemotherapy</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Individual assessment </li>
    <li>Combination chemotherapy
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Carboplatin and paclitaxel (C-P) </li>
        <li>Carboplatin and gemcitabine </li>
        <li>Carboplatin and pegylated liposomal doxorubicin (C-PLD) </li>
    </ul>
    </li>
    <li>Single agent chemotherapy
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Carboplatin </li>
        <li>Paclitaxel </li>
        <li>Topotecan </li>
        <li>Pegylated liposomal doxorubicin </li>
        <li>Gemcitabine </li>
    </ul>
    </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Progression-free survival (PFS) </li>
    <li>Overall survival (OS) </li>
    <li>Adverse events </li>
    <li>Quality of life (QOL) </li>
    <li>Tumour response rates </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Hand-searches of Published Literature (Primary Sources)"/>
      <fieldvalue value="Hand-searches of Published Literature (Secondary Sources)"/>
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Literature Search Strategy</strong></p>
<p>The literature was searched using MEDLINE and EMBASE (OVID: 2006 through March 2011), the Cochrane Library (OVID: Cochrane Central Register of Controlled Trials 1st Quarter 2011, Cochrane Database of Systematic Reviews 2005 to March 2011), the Canadian Medical Association Infobase, and the National Guideline Clearinghouse. In addition, the abstracts published in the proceedings of the meetings of the American Society of Clinical Oncology (2005-2011) and the European Society for Medical Oncology (2006, 2008, 2010) were searched for evidence relevant to this report. Reference lists of related papers and recent review articles were also scanned for additional citations.</p>
<p>The literature search of the electronic databases was adopted from the previous version of the guideline and combined the terms (ovarian neoplasms/ or ovarian.ti. and neoplasm:.mp. or cancer.mp.) with (neoplasm recurrence local/ or neoplasm metastasis/ or recurrent:.mp. or relapse:.mp. or resistance.mp.) and (drug therapy/ or antineoplastic agents/ or chemotherapy.mp.) for the following study designs: randomized controlled trials, meta-analyses, practice guidelines, and systematic reviews.</p>
<p>The review also included a search for results from the trials in progress when the previous version of this guideline was published: the Southwest Oncology Group Protocol (SWOG) S0200, Carboplatin-Paclitaxel (C-P) Versus Carboplatin-Pegylated Liposomal Doxorubicin (C-PLD) In Platinum-Sensitive Patients (CALYPSO), and International Collaboration for Ovarian Neoplasia 6 (ICON6).</p>
<p><strong>Inclusion Criteria</strong></p>
<p>Articles were selected for inclusion in the systematic review if they were phase III randomized controlled trials that compared chemotherapeutic agents as part of second or greater line treatment for patients with recurrent epithelial ovarian cancer who were previously treated with platinum-containing chemotherapy. Trials were to report data on at least one of the following outcomes of interest: overall survival (OS), progression-free survival (PFS), adverse events, or quality of life (QOL). Tumour response rate was also considered an outcome of interest. Practice guidelines, meta-analyses, or systematic reviews explicitly based on randomized trials related to the guideline question were also eligible for inclusion.</p>
<p><strong>Exclusion Criteria</strong></p>
<p>Articles were excluded from the systematic review if they were reported in a language other than English, or if they included the use of intraperitoneal chemotherapy, hormonal therapy, or chemotherapy with bone marrow or stem cell transplantation. Abstracts reporting analyses that were conducted before predetermined trial endpoints were reached were also excluded.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The literature search conducted in 2011 identified six phase III randomized trials comparing various chemotherapy regimens for women with recurrent ovarian cancer.</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Expert Consensus (Committee)"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Methodological Quality Appraisal of Randomized Controlled Trials</strong></p>
<p>Randomized trials that met the inclusion criteria were assessed using information provided in the trial reports: randomization sequence generation, allocation concealment, blinding, analysis details including intention-to-treat analysis, withdrawals, loss to follow-up, funding source, statistical power calculations, length of follow-up, and differences in baseline patient characteristics.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Methods</strong></p>
<p>The Evidence-Based Series (EBS) guidelines developed by the Program in Evidence-Based Care (PEBC), Cancer Care Ontario, use the methods of the Practice Guidelines Development Cycle. For this project, the core methodology used to develop the evidentiary base was the systematic review. The initial evidence review was conducted by a PEBC methodologist and the studies identified for inclusion were reviewed by the remaining members of the Working Group.</p>
<p>The systematic review is a convenient and up-to-date source of the best available evidence on chemotherapy for the treatment of women with recurrent epithelial ovarian cancer. The body of evidence in this review is comprised of data from phase III randomized controlled trials. That evidence forms the basis of the recommendations found in Section 1 of this EBS.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="External Peer Review"/>
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Report Approval Panel (RAP) Review and Approval</strong></p>
<p>Prior to the submission of this Evidence-Based Series (EBS) draft report for External Review, the report was reviewed and approved by the Program in Evidence-based Care (PEBC) RAP, a panel that includes oncologists and whose members have clinical and methodological expertise.</p>
<p><strong>External Review by Ontario Clinicians and Other Experts</strong></p>
<p>The PEBC external review process is two-pronged and includes a targeted peer review that is intended to obtain direct feedback on the draft report from a small number of specified content experts and a professional consultation that is intended to facilitate dissemination of the final guidance report to Ontario practitioners.</p>
<p>Following the review and discussion of Section 1: Recommendations and Section 2: Evidentiary Base in the original guideline document of this EBS and the review and approval of the report by the PEBC RAP, the working group circulated Sections 1 and 2 to external review participants for review and feedback.</p>
<p><em>Methods</em></p>
<p><span style=&quot;text-decoration: underline;&quot;>Targeted Peer Review</span></p>
<p>During the guideline development process, two targeted peer reviewers from Ontario and one from British Columbia, considered to be clinical and/or methodological experts on the topic, were identified by the Working Group. Several weeks prior to completion of the draft report, the nominees were contacted by email and asked to serve as reviewers. Two reviewers agreed and the draft report and a questionnaire were sent via email for their review. The questionnaire consisted of items evaluating the methods, results, and interpretive summary used to inform the draft recommendations and whether the draft recommendations should be approved as a guideline. Written comments were invited. The questionnaire and draft document were sent out on September 28, 2011. Follow-up reminders were sent at two weeks (email) and at four weeks (telephone call). The Working Group reviewed the results of the survey.</p>
<p><span style=&quot;text-decoration: underline;&quot;>Professional Consultation</span></p>
<p>Feedback was obtained through a brief online survey of health care professionals in Ontario who are the intended users of the guideline. All individuals in the PEBC database who were identified as having an interest in gynecology and radiation or surgery or systemic treatment were contacted by email to inform them of the survey. Participants were asked to rate the overall quality of the guideline (Section 1 in the original guideline document) and whether they would use and/or recommend it. Written comments were invited. Participants were contacted by email and directed to the survey website where they were provided with access to the survey, the guideline recommendations (Section 1 in the original guideline document) and the evidentiary base (Section 2 in the original guideline document). A paper copy was also delivered to each person. The notification email was sent on September 28, 2011. The consultation period ended on November 11, 2011. The Working Group reviewed the results of the survey.</p>
<p><strong>Conclusion</strong></p>
<p>This EBS report reflects the integration of feedback obtained through the external review process, with final approval given by the Gynecologic Cancer Disease Site Group and the RAP of the PEBC. Updates of the report will be conducted as new evidence informing the question of interest emerges.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The recommendations are supported by randomized trials.</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Patients with Platinum-sensitive Ovarian Cancer</strong></p>
<p>A 976 patient study, Carboplatin-Pegylated Liposomal Doxorubicin (C-PLD) In Platinum-Sensitive Patients (CALYPSO), compared carboplatin-paclitaxel (C-P) to C-PLD and found an improvement in progression-free survival (PFS) with the PLD combination (11.4 versus [vs.] 9.3 months, p=0.005), a more favourable toxicity profile, no difference in overall survival (OS) (although significantly more patients crossed over to the C-PLD arm), and a superior crossover treatment rate in the C-P arm. Global quality of life (QOL) scores did not differ between groups.</p>
<p><strong>A Mix of Platinum-sensitive and Platinum-resistant Patients</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>A 672 patient study, OVA-301, compared PLD to trabectedin-PLD, and found a statistically significantly improved PFS with the combination (7.3 vs. 5.8 months, p=0.019). Despite this finding, which implies the viability of the combination as a treatment option, the trabectedin-PLD combination is not recommended at this time, based on the finding of no differences in QOL or OS, the lack of clinical significance of a six-week PFS difference, the lack of comparison with the Gynecologic Cancer Intergroup (GCIG) standard taxane and platinum agent, and the elevated rate of adverse events such as raised liver enzymes, non-fatal congestive heart failure, and neutropenia in the combination group. </li>
    <li>A study by Sehouli et al. of topotecan versus topotecan combined with other agents did not find a benefit with the combination therapy in a population of mainly platinum-sensitive women; thus, topotecan combination therapy is not recommended. </li>
    <li>Two smaller trials that compared PLD with gemcitabine showed no difference in PFS. A small significant difference in OS was found in one trial (56 weeks for PLD vs. 51 weeks for gemcitabine, p=0.048). The adverse events profiles differ for these two agents; therefore, gemcitabine can be considered another option in this patient population, considering patient preference and previous toxicity. </li>
</ul></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Adverse Events Associated with Chemotherapy</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>As seen in Table 3 in the original guideline document, data on adverse events varied by treatment regimen, and, while there were differences in reporting, outcomes correlated with known toxicity profiles. </li>
    <li>Ten trials reported statistically significant differences in adverse events by treatment group. On average, severe adverse events, generally haematological, were significantly associated with combination chemotherapy when compared with single-agent chemotherapy. The agents most commonly used were paclitaxel, carboplatin, topotecan, and pegylated liposomal doxorubicin. Adverse events associated with paclitaxel included alopecia (any grade) in 62% to 100% of patients, neurotoxic effects (any grade) in 5% to 42% of patients, severe leukopenia in 4% to 24% of patients, and severe nausea and vomiting in 2% to 6% of patients. Carboplatin was associated with low severe hematological events, typically less than 15% of patients, severe nausea and vomiting in approximately 10% or less of patients, and any grade of alopecia in 2% to 25% of patients. When compared with paclitaxel or pegylated liposomal doxorubicin, topotecan was significantly associated with increased severe haematological toxicities, and some grade of alopecia occurred in 49% and 76% of patients. The adverse events associated with pegylated liposomal doxorubicin included any grade of palmar-plantar erythrodysesthesia (PPE) in approximately one half of patients, and severe PPE occurred in 23% and 16% of patients, respectively. One trial also reported a significant difference in severe stomatitis in patients treated with pegylated liposomal doxorubicin when compared with paclitaxel (10% versus 1%; p=0.03).</li>
</ul></div>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>The results presented in an abstract from <em>A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)</em>, a randomized, 484-person, double-blinded, placebo-controlled phase III trial of carboplatin and gemcitabine with or without bevacizumab (Bev) in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer showed a significantly longer progression-free survival (PFS) in the Bev arm (8.4 months vs. 12.4 months, p&amp;lt;0.0001). While no recommendation for this treatment option is being made at this time, the publication of the full results of this trial is anticipated and may inform future guideline recommendations. </li>
    <li>A recommendation for trabectedin-pegylated liposomal doxorubicin (PLD) for carboplatin and cisplatin allergic patients may be reasonable, however because the PFS benefit with this combination was modest, and there was no overall survival (OS) difference, a recommendation for this combination is not being made at this time. </li>
    <li>Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way. </li>
</ul>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An implementation strategy was not provided.</p></div>"/>
    </field>
    <field fieldid="117" ordby="1015" id="437" name="Implementation Tools" type="picklist-many">
      <fieldvalue value="Quick Reference Guides/Physician Guides"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Getting Better"/>
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Patient-centeredness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Fung Kee Fung M, Kennedy E, Francis J, Mackay H, Gynecologic Cancer Disease Site Group. Optimal chemotherapy for recurrent ovarian cancer. Toronto (ON): Cancer Care Ontario (CCO); 2011 Nov 21. Various p.&amp;nbsp;(Evidence-based series; no. 4-3).&amp;nbsp; [89 references]</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2001 Sep 21 (revised 2011 Nov 21)"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]"/>
    </field>
    <field fieldid="123" ordby="1230" id="448" name="Guideline Developer Comment" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.</p></div>"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The Program in Evidence-based Care (PEBC) is a provincial initiative of Cancer Care Ontario supported by the Ontario Ministry of Health and Long-Term Care through Cancer Care Ontario. All work produced by the PEBC is editorially independent from its funding source.</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Gynecologic Cancer Disease Site Group</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>For a current list of past and present members, please see the <a href=&quot;https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&amp;amp;pageId=10245&quot; title=&quot;Cancer Care Ontario Web site&quot;>Cancer Care Ontario Web site</a>.</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>In accordance with the Program in Evidence-based Care (PEBC) Conflict of Interest Policy, the guideline authors, Gynecologic Cancer Disease Site Group (DSG) members, and internal and external reviewers were asked to disclose potential conflicts of interest. The authors, members, and reviewers reported that they had no conflicts of interest.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Fung Kee Fung M, Johnston M, Eisenhauer E, Elit L, Hirte H, Rosen R and the Gynecological Cancer Disease Site Group. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum. Toronto (ON): Cancer Care Ontario (CCO); 2001 Sep 21. (Evidence Summary Report No. 4-3).</p>
<p>The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from reviewing and updating activities.</p>
<p>Please visit the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34203&quot; title=&quot;CCO Web site&quot;>Cancer Care Ontario Web site</a> for details on any new evidence that has emerged and implications to the guidelines.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34203&quot; title=&quot;Cancer Care Ontario Web site&quot;>Cancer Care Ontario Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following are available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Optimal chemotherapy for recurrent ovarian cancer. Summary. Toronto (ON): Cancer Care Ontario; 2011 Nov 21. 8 p. Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=14094&quot; title=&quot;Cancer Care Ontario (CCO) Web site&quot;>Cancer Care Ontario (CCO) Web site</a>. </li>
    <li>Program in Evidence-Based Care (PEBC) handbook. Toronto (ON): Cancer Care Ontario (CCO); 2012. 14 p. Electronic copies: Available in PDF from the <a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=50876&quot; title=&quot;Cancer Care Ontario (CCO) Web site&quot;>CCO Web site</a>. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on September 6, 2013.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please refer to the <a href=&quot;http://www.cancercare.on.ca/ontariocancernews/copyright.html&quot; title=&quot;CCO Web site&quot;>Copyright and Disclaimer Statements</a> posted at the Cancer Care Ontario Web site.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <a href=&quot;/about/inclusion-criteria.aspx&quot;>http://www.guideline.gov/about/inclusion-criteria.aspx</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 21:56:07 Sep 30, 2016 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 01:15:05 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 742.478 (3)
  esindex: 0.015
  captures_list: 771.0
  CDXLines.iter: 21.964 (3)
  PetaboxLoader3.datanode: 430.535 (4)
  exclusion.robots: 0.486
  exclusion.robots.policy: 0.462
  RedisCDXSource: 0.89
  PetaboxLoader3.resolve: 675.121 (4)
  load_resource: 385.555
-->